₹-41.20
(Market cap
₹2,973 Cr
Recently Viewed
Clear AllMarket cap
₹2,973 Cr
Revenue (TTM)
₹480 Cr
P/E Ratio
90.8
P/B Ratio
3.9
Div. Yield
0.1 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹33 Cr
ROE
0.8 %
ROCE
1.2 %
Industry P/E
22.69
EV/EBITDA
38.7
Debt to Equity
0
Book Value
₹329
EPS
₹14
Face value
10
Shares outstanding
23,392,055
CFO
₹268.94 Cr
EBITDA
₹490.33 Cr
Net Profit
₹325.76 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Tatva Chintan
| -4.8 | 13.5 | 9.8 | 71.6 | -8.1 | -- | -- |
|
BSE Commodities
| 5.1 | 15.1 | 5.2 | 14.0 | 18.0 | 13.5 | 16.0 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Tatva Chintan
| 55.3 | -44.4 | -25.5 | -19.0 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 |
|
BSE Commodities
| 12.5 | 8.1 | 17.5 | 1.2 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Tatva Chintan
|
1,269.9 | 2,973.4 | 479.6 | 32.8 | 8.3 | 4.4 | 90.8 | 3.9 |
| 1,475.6 | 7,551.7 | 1,535.0 | 180.7 | 13.7 | 12.7 | 41.8 | 5.1 | |
| 3,650.2 | 15,795.8 | 15,069.6 | 378.2 | 3.0 | 9.9 | 41.8 | 4.1 | |
| 1,221.9 | 15,496.6 | 11,162.0 | 877.2 | 12.4 | 13.7 | 17.7 | 2.3 | |
| 1,764.5 | 6,251.4 | 5,078.5 | 280.8 | 7.1 | 11.9 | 22.3 | 2.4 | |
| 769.5 | 5,652.1 | 4,308.2 | 34.3 | 0.0 | -0.2 | -- | 1.0 | |
| 2,484.2 | 7,958.8 | 15,622.2 | 1,787.5 | 16.6 | 12.6 | 8.8 | 1.0 | |
| 4,920.4 | 6,666.5 | 1,886.6 | 168.0 | 11.4 | 16.6 | 39.7 | 5.0 | |
| 6,452.0 | 33,114.3 | 3,077.1 | 545.9 | 25.9 | 18 | 60.7 | 8.7 | |
| 693.3 | 17,682.6 | 14,655.0 | 194.0 | 4.8 | 1.2 | 98.2 | 0.8 |
Analyst's Diary: Out of season
4 min read•By Hemkesh Khattar
IPO update: Tatva Chintan Pharma Chem
3 min read•By Udhayaprakash
Tatva Chintan Pharma: IPO analysis
6 min read•By Rajan Gulati
Tatva Chintan Pharma Chem Limited engages in manufacture and sale of specialty chemicals in India. The company offers a portfolio of structure directing agents for zeolites synthesis; phase transfer catalysts; electrolyte salts for super capacitor... and zinc ion batteries; and pharmaceutical APIs, agrochemical products, and other specialty chemicals in the form of intermediates, disinfectants, catalysts, and solvents. It also engages in trading of specialty chemicals. The company serves various industries, including the automotive, petroleum, pharmaceutical, agro-chemicals, paints and coatings, dyes and pigments, personal care, and flavor and fragrances industries. It also exports its products to various countries, including the United States, Singapore, the United Kingdom, China, Germany, Japan, and South Africa. The company was incorporated in 1996 and is headquartered in Vadodara, India. Read more
Incorporated
1996
Chairman
Chintan Nitinkumar Shah
Managing Director
Chintan Nitinkumar Shah
Headquarters
Bharuch, Gujarat
Website
Looking for more details about Tatva Chintan Pharma Chem Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Tatva Chintan Pharma Chem Ltd is ₹1,269.90 (NSE) and ₹1,271.10 (BSE) as of 24-Apr-2026 IST. Tatva Chintan Pharma Chem Ltd has given a return of -8.06% in the last 3 years.
The P/E ratio of Tatva Chintan Pharma Chem Ltd is 90.75 times as on 24-Apr-2026, a 300 premium to its peers’ median range of 22.69 times.
The P/B ratio of Tatva Chintan Pharma Chem Ltd is 3.86 times as on 24-Apr-2026, a 124 premium to its peers’ median range of 1.72 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
278.00
|
2.15
|
|
2024
|
83.19
|
3.43
|
|
2023
|
81.23
|
7.18
|
|
2022
|
53.35
|
10.81
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Tatva Chintan Pharma Chem Ltd are Rs 1,610.00 and Rs 672.00 as of 24-Apr-2026.
Tatva Chintan Pharma Chem Ltd has a market capitalisation of ₹ 2,973 Cr as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Tatva Chintan Pharma Chem Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.